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IMMUNOSUPPRESSION
Peripheral Blood Lymphocyte Phenotype Can Predict Rejection
Episodes After Orthotopic Liver Transplantation
R. Perdigoto, A. Paiva, A. Freitas, H. Breˆda Coimbra, O. Mota, J. Ferra˜o, L. Tome´, E. Furtado,
M.A. Cipriano, B. Geraldes, F.J. Oliveira, and A.L. Furtado
IT IS WIDELY known that, unlike other transplants, liverallografts behave as an immunologically favored organ
and that their outcome is apparently independent of HLA
compatibility, showing a special tolerance status and pro-
longed survival.1 It is also known that controling rejection is
the most important aspect in the treatment of posttrans-
plant recipients because it determines prognosis.2
Changes in T-lymphocyte (Ly) subsets have previously
been related to clinical events following liver transplanta-
tion and have been of prognostic significance following
renal transplantation.3 Activation and proliferation of im-
munocompetent cells is the basic immunologic response to
alloantigens,4 which could be evaluated by the expression
on T cells of CD25, HLA-DR molecules, and by the loss of
the high molecular mass isoform of the CD45 molecule
(CD45RA) and the expression of the low molecular mass
isoform CD45RO.5 Also, the increase of CD81 Ly coex-
pressing the CD57 molecule has been found in graft
rejection episodes.6 Furthermore, Ly adhesion to the endo-
thelium and Ly migration from blood to tissues are critical
steps in cellular rejection and depend on cytokine-induced
expression of endothelial adhesion molecules. Ly may bind
to the endothelium by ICAM-1 (CD54), VCAM-1, and
E-selectin–dependent pathways.7
The aim of our study was to detect phenotypic changes in
peripheral blood Ly of liver transplanted patients, in the
absence of bacterial, viral, or fungal infections, in order to
predict rejection episodes. For this purpose, we studied
patients at pretransplant, twice a week in the first month,
and 3, 6, 9, and 12 months after orthotopic liver transplan-
tation (OLT). Immunophenotyping was made by flow cy-
tometry and Ly populations and subpopulations were char-
acterized by the following markers: CD3, CD16/CD56,
CD19, CD4, CD8, CD4/CD45RA, CD4/CD45RO, CD8/
CD56, CD8/CD57, CD4/CD25, CD8/CD25, CD4/HLA-
DR, CD8/HLA-DR, CD4/CD54, and CD8/CD54.
MATERIALS AND METHODS
Patients
We studied 32 patients immediately before OLT and two times a
week in the first month and at the 3rd, 6th, 9th, and 12th month
after OLT.
Methods
Cell immunophenotyping was performed with fluorochrome (or-
der: FITC/PE/TC)-conjugated monoclonal antibodies (MøAbs) by
standard three-color immunofluorescence: CD3/CD161CD56/
CD19; CD45RA/CD45RO/CD4; HLA-DR/CD25/CD4; CD57/
CD56/CD8; HLA-DR/CD25/CD8; and CD4/CD54/CD8. All
MøAbs were purchased from Immunotech (Coulter Company,
France), except TC-conjugated CD4, CD8, CD19 (Caltag Lab,
Calif), and FITC-conjugated CD4 (Serotec Lda, UK).
Briefly, 100 mL of EDTA collected venopuncture blood was
incubated with an appropriate volume of MøAb for 10 minutes at
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room temperature in the dark, followed by red blood cell lysis
(Q-PREP, Coulter, Hialeah, Fla). Cells were washed once, resus-
pended with 0.7 mL of phosphate buffer saline with 1% parafor-
maldehyde, and 10,000 events were analyzed on an Epics XL
(Coulter) flow cytometer.
Statistical Analysis
Statistical analysis was carried out using a standard t test performed
by Macintosh (Cupertino, Calif) computer program Statview 5121
(Abacus, Berkeley, Calif).
RESULTS
Our results in the first days after OLT showed a significant
increase in B Ly, a significant decrease in T Ly and their
subpopulations CD4 and CD8, and the same percentage of
natural killer (NK) cells, which tend to return to pretrans-
plant values around the third week after transplantation.
The other Ly subpopulations did not change after OLT,
except the T-cell subset CD41/CD541 which increased
(Table 1).
Immediately before or during rejection episodes, we
observed an increase in the percentage of CD8/CD57,
CD8/CD56, CD8/CD54, CD8/HLA-DR, CD4/CD45RO,
CD4/CD54, and CD4/CD25 double-positive Ly and a de-
crease in CD4/CD45RA double-positive Ly (Table 2).
DISCUSSION
Despite the difference in the HLA complex between the
donor and the receptor in OLT, the incidence and severity
of unresolved acute and chronic rejection episodes are less
common than in other solid organ transplants. Liver allo-
graft rejection is mediated by a primary response of T Ly
followed by infiltration of the graft with a mixed inflamma-
tory reaction.8
Peripheral blood Ly analysis by flow cytometry, before
and after OLT, could be useful in predicting acute rejection
episodes,1 despite the controversial applications in renal
transplantation.9 We found major alterations in the per-
centage of T (CD3, CD4 and CD8) and B Ly after OLT.
Almost all subpopulations of CD4 and CD8 Ly remained
unchanged, except the subpopulation CD41/CD541,
which allows detection of percent changes on the other
T-cell subsets and correlates them with rejection/infection
episodes. Immediately before or during rejection episodes,
our results showed in CD41 Ly an increase in CD45RO,
CD54, and CD25, and a decrease in CD45RA double-
positive cells. An increase of CD54, HLA-DR, CD56, and
CD57 was observed in CD81 Ly on rejection episodes. This
increase of activated T Ly and CD8 Ly with higher cytolytic
potential is in agreement with other studies performed in
kidney transplantation.9 The immune response to infection
could induce similar changes in T-Ly subsets. In order to
analyze if the noted changes were able to discriminate
between infection or rejection episodes, we treated our
results as a ratio of increase (data not shown). Although the
number of cases of rejection or infection has been small, the
subsets CD4/CD45RO, CD25/CD4, CD56/CD8, CD57/
CD8, and HLA-DR/CD8 presented a higher ratio on
rejection than infection, and could be used as a good
marker of rejection episodes.
Table 1. Percentage (Mean 6 SD) of B, T, and NK Ly and
Subpopulations of T Ly Coexpressing Other Molecules Before
and in the First Days After OLT
Cell Populations Before OLT After OLT
CD3 76 6 9* 50 6 15
CD19 14 6 7* 40 6 15
CD16/CD56 7 6 6 7 6 5
CD4 51 6 10* 32 6 11
CD8 24 6 6* 18 6 6
CD45RO on CD41 69 6 18 62 6 18
CD45RA on CD41 36 6 20 40 6 20
CD25 on CD41 15 6 9 13 6 8
HLA-DR on CD41 6 6 3 7 6 4
CD54 on CD41 13 6 6* 26 6 12
CD56 on CD81 19 6 17 22 6 12
CD57 on CD81 25 6 17 25 6 16
CD25 on CD81 3 6 3 3 6 2
HLA-DR on CD81 13 6 7 11 6 6
CD54 on CD81 30 6 13 34 6 16
*Statistically significant value (P , .05).
Table 2. Percentage (Mean 6 SD) of T Ly and Subpopulations of CD4 and CD8 Ly Coexpressing Other Molecules on the Last
Immunophenotyping Before Rejection Episodes (BRE) and on Rejection Episodes (RE)
CD3 CD4 CD8
CD45RA
on CD4
CD45RO
on CD4
CD25 on
CD4
HLA-DR
on CD4
CD54 on
CD4
CD56 on
CD8
CD57 on
CD8
CD25 on
CD8
HLA-DR
on CD8
CD54 on
CD8
JAG BRE 54 39 28 32 63 6 13 25 23 65 1 21 35
JAG on RE 79 56 26 37 72 28 15 36 43 75 7 35 55
MFS BRE 58 49 12 43 70 12 3 18 21 28 4 14 17
MFS on RE 75 55 18 36 77 29 5 33 28 34 8 18 74
VWF BRE 95 71 22 51 45 26 2 14 5 12 6 8 27
VWF on RE 94 68 23 43 54 27 4 23 9 20 6 14 38
JJAS BRE 61 34 23 47 53 6 6 – 10 11 1 6 –
JJAS on RE 61 32 22 27 72 12 5 – 17 13 1 7 –
MHZC BRE 48 37 12 65 34 5 3 – 8 9 2 7 –
MHZC on RE 55 38 19 51 53 22 7 – 25 22 3 19 –
Abbreviations: JAG; MFS; VWF; JJAS; MHZC.
LYMPHOCYTE PHENOTYPE 2419
REFERENCES
1. Garcı´a-Alonso AM, Minguela A, Muro M, et al: Hum
Immunol 53:64, 1997
2. Sakurai H, Mizuno S, Ohtakara K, et al: Transplant Proc
26:898, 1994
3. Crosbie OM, Norris S, Hegarty JE, et al: Immunol Invest
27:237, 1998
4. Nakajima Y, Hisanaga M, Taki J, et al: Transplantation
55:480, 1993
5. Ibrahim S, Dawson DV, Sanfilippo F: Transplantation 59:724,
1995
6. Lebranchu Y, Kapahi P, Najjar Al, et al: Transplant Proc
26:1873, 1994
7. Hebib C, Leroy E, Rouleau M, et al: Transplant Immunol
6:39, 1998
8. Dollinger MM, Howie SE, Plevris JN, et al: FASEB J 12:939,
1998
9. Oliveira JGG, Ramos JP, Xavier P, et al: Transplantation
64:97, 1997
2420 PERDIGOTO, PAIVA, FREITAS ET AL
